Acute Pain Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Hyloris Pharma, AFT Pharma, Formosa Pharma

Posted on
by

Acute Pain Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Hyloris Pharma, AFT Pharma, Formosa Pharma
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Pain pipeline constitutes 25+ key companies continuously working towards developing 25+ Acute Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

“Acute Pain Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Pain Market.

 

Some of the key takeaways from the Acute Pain Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Acute Pain treatment therapies with a considerable amount of success over the years. 
  • Acute Pain companies working in the treatment market are Virpax Pharmaceuticals, Bexson Biomedical, Sparian Biosciences, Inc, Kures Therapeutics, Vertex Pharmaceuticals, Allay Therapeutics, Inc, Scilex Pharmaceuticals, Vivozon Pharmaceutical, Pharmbio Korea Co., Ltd., and others, are developing therapies for the Acute Pain treatment 
  • Emerging Acute Pain therapies in the different phases of clinical trials are- NES-100, BB-106, SBS-1000, KUR-101, VX-708, ATX-101, SP-103, VVZ-149, PBK_L1704, VX-548, and others are expected to have a significant impact on the Acute Pain market in the coming years.   
  • In January 2023, A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain was started by Vertex Pharmaceuticals Incorporated. This study aims to assess the efficacy and safety of VX-548 in the treatment of acute pain.
  • In October 2022, “A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy” is the name of the trial that Vertex Pharmaceuticals Incorporated started.
  • In August 2022, The FDA had designated Vertex Pharmaceuticals’ experimental oral medication VX-548 as a breakthrough therapy for the management of patients experiencing moderate-to-severe acute pain.
  • In March 2022, Positive outcomes from two Phase II proof-of-concept (POC) studies examining the use of the selective NaV1.8 inhibitor VX-548 for the management of acute pain following bunionectomy or abdominoplasty surgery were reported by Vertex Pharmaceuticals Incorporated.

 

Acute Pain Overview

Acute pain happens suddenly, starts out sharp or intense, and serves as a warning sign of disease or threat to the body. It Is caused by injury, surgery, illness, trauma, or painful medical procedures and generally lasts from a few minutes to less than six months.

 

Get a Free Sample PDF Report to know more about Acute Pain Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-pain-pipeline-insight

 

Emerging Acute Pain Drugs Under Different Phases of Clinical Development Include:

  • NES-100: Virpax Pharmaceuticals
  • BB-106: Bexson Biomedical
  • SBS-1000: Sparian Biosciences, Inc
  • KUR-101: Kures Therapeutics
  • VX-708: Vertex Pharmaceuticals
  • ATX-101: Allay Therapeutics, Inc
  • SP-103: Scilex Pharmaceuticals
  • VVZ-149: Vivozon Pharmaceutical
  • PBK_L1704: Pharmbio Korea Co., Ltd.
  • VX-548: Vertex Pharmaceuticals

 

Acute Pain Route of Administration

Acute Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Acute Pain Molecule Type

Acute Pain Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Acute Pain Pipeline Therapeutics Assessment

  • Acute Pain Assessment by Product Type
  • Acute Pain By Stage and Product Type
  • Acute Pain Assessment by Route of Administration
  • Acute Pain By Stage and Route of Administration
  • Acute Pain Assessment by Molecule Type
  • Acute Pain by Stage and Molecule Type

 

DelveInsight’s Acute Pain Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Acute Pain product details are provided in the report. Download the Acute Pain pipeline report to learn more about the emerging Acute Pain therapies

 

Some of the key companies in the Acute Pain Therapeutics Market include:

Key companies developing therapies for Acute Pain are – Hyloris Pharmaceuticals, AFT Pharmaceuticals, Formosa Pharmaceuticals, Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International (MVP), Neumentum Pharmaceuticals, Charleston Laboratories, Neurana Pharmaceuticals, AcelRx Pharmaceuticals, Teikoku Pharma, PainReform, Nevakar, Unither Pharmaceuticals, Aptys Pharmaceuticals, Avenue Pharmaceuticals, and others.

 

Acute Pain Pipeline Analysis:

The Acute Pain pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acute Pain with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Pain Treatment.
  • Acute Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Acute Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Pain market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acute Pain drugs and therapies

 

Acute Pain Pipeline Market Drivers

  • Increase in prevalence of Acute Pain, numerous government bodies and healthcare organizations taking initiatives to improve pain management practices are some of the important factors that are fueling the Acute Pain Market.

 

Acute Pain Pipeline Market Barriers

  • However, pain assessment and management in older adults have inherent challenges, cost associated with the treatment and other factors are creating obstacles in the Acute Pain Market growth.

 

Scope of Acute Pain Pipeline Drug Insight    

  • Coverage: Global
  • Key Acute Pain Companies: Virpax Pharmaceuticals, Bexson Biomedical, Sparian Biosciences, Inc, Kures Therapeutics, Vertex Pharmaceuticals, Allay Therapeutics, Inc, Scilex Pharmaceuticals, Vivozon Pharmaceutical, Pharmbio Korea Co., Ltd., and others
  • Key Acute Pain Therapies: NES-100, BB-106, SBS-1000, KUR-101, VX-708, ATX-101, SP-103, VVZ-149, PBK_L1704, VX-548, and others
  • Acute Pain Therapeutic Assessment: Acute Pain current marketed and Acute Pain emerging therapies
  • Acute Pain Market Dynamics: Acute Pain market drivers and Acute Pain market barriers 

 

Request for Sample PDF Report for Acute Pain Pipeline Assessment and clinical trials

 

Table of Contents

1. Acute Pain Report Introduction

2. Acute Pain Executive Summary

3. Acute Pain Overview

4. Acute Pain- Analytical Perspective In-depth Commercial Assessment

5. Acute Pain Pipeline Therapeutics

6. Acute Pain Late Stage Products (Phase II/III)

7. Acute Pain Mid Stage Products (Phase II)

8. Acute Pain Early Stage Products (Phase I)

9. Acute Pain Preclinical Stage Products

10. Acute Pain Therapeutics Assessment

11. Acute Pain Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Pain Key Companies

14. Acute Pain Key Products

15. Acute Pain Unmet Needs

16 . Acute Pain Market Drivers and Barriers

17. Acute Pain Future Perspectives and Conclusion

18. Acute Pain Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services